ICON Public (NASDAQ:ICLR) Lowered to Neutral at Robert W. Baird

Robert W. Baird lowered shares of ICON Public (NASDAQ:ICLR) from an outperform rating to a neutral rating in a report released on Thursday, Marketbeat Ratings reports. They currently have $340.00 price objective on the medical research company’s stock.

Other equities research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Barclays decreased their price target on shares of ICON Public from $350.00 to $330.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 15th. Truist Financial cut their price objective on shares of ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a research report on Monday, October 14th. Leerink Partners began coverage on ICON Public in a report on Wednesday, September 18th. They issued an “outperform” rating and a $379.00 price target for the company. Finally, Evercore ISI cut their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and an average target price of $336.18.

ICON Public Stock Performance

NASDAQ:ICLR opened at $227.54 on Thursday. The firm has a market capitalization of $18.77 billion, a PE ratio of 27.23, a PEG ratio of 1.35 and a beta of 1.22. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36. ICON Public has a 1 year low of $220.51 and a 1 year high of $347.72. The firm’s fifty day simple moving average is $299.79 and its 200 day simple moving average is $310.96.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the firm posted $3.10 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, sell-side analysts anticipate that ICON Public will post 14.54 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ICLR. Ashton Thomas Private Wealth LLC acquired a new position in shares of ICON Public during the second quarter valued at $54,000. ORG Partners LLC bought a new stake in shares of ICON Public during the second quarter worth approximately $59,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in ICON Public by 410.8% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock valued at $63,000 after buying an additional 152 shares during the period. GAMMA Investing LLC raised its position in shares of ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 42 shares during the period. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.